Protocols · III
Bundle·2 compounds · save 10%

Stack III

The Metabolic Stack

Incretin / amylin co-agonism research

GLP-1 receptor agonist paired with a long-acting amylin analog — the current frontier in metabolic co-agonism research.

Stack price

Combined$0
Stack savings− $0
Total$0

+ 12% additional crypto discount at checkout

Protocol map

The compounds, in order.

Why these together

Rationale

Semaglutide is a long-acting GLP-1 receptor agonist studied for glycemic regulation and central satiety signaling. Cagrilintide is a long-acting amylin analog studied for complementary satiety pathway activation. Their combined co-administration is an active area of metabolic and energy-expenditure research.

Compounds in this stack

Recent batches

The ledger,
open.

Every batch sent for independent HPLC analysis at Janoshik Analytical. Results published the moment they land — no editorial pass, no rounding.

Compound
Purity
Batch
COA
Cagrilintide
5mg · metabolic
99.0%
2026-06-02
Dihexa
15mg · cognitive
98.5%
2026-06-02
Tesamorelin
10mg · growth
99.2%
2026-05-30
Thymosin Alpha-1
5mg · recovery
99.1%
2026-05-30
Cerebrolysin
215mg · cognitive
99.4%
2026-05-28

Showing 5 of 24

Methodology